The number of pipeline Drug Delivery products in 2021 saw a 21% rise globally when compared to Drug Delivery pipeline products in 2020, according to GlobalData’s pipeline products database. This compares to an 15% rise for all pipeline medical devices in 2021 compared to 2020.
The global Drug Delivery Devices market was worth $3.05bn in 2020 and is expected to reach $3.21bn by 2025, according to GlobalData’s analysis.
Drug Delivery Devices pipeline products by categories: Injectable Drug Delivery has the most devices
Looking at the device categories of pipeline products, Injectable Drug Delivery accounted for the largest proportion (21.05%) in 2021, followed by Transdermal Drug Delivery (12.5%) and Infusion Systems (9.87%).
Of the global medical devices market value, the Drug Delivery Devices market held a 1% share worth $3bn in 2021 and is expected to reach $3.21bn by 2025.
Drug Delivery Devices development activity: Advanced stage of development leads
Devices at an advanced stage of development (in clinical trials, in the approval process, already approved in Europe or the rest of the world) accounted for 36.18% of medical devices in 2021, compared with 46.15% in 2020. The number of devices at the In Approval stage declined by 38% in 2021, when compared with 2020.
The In Approval stage is considered to be the period where the manufacturer is waiting for final approval from regulators, following completion of the required development steps.
A decrease in products awaiting approval would indicate less new products entering the market in the coming months, while an increase indicates more devices entering the market, posing a market share threat to existing marketed devices.
North America tops pipeline Drug Delivery Devices products activity
Comparing the number of pipeline Drug Delivery Devices products activity in different regions of the globe, North America held the top position (58%) during 2021, followed by Europe (25%), and Asia-Pacific (14%).
On a country level, the US had the most pipeline Drug Delivery Devices during the year, representing the largest share (65%) of Drug Delivery pipeline products. In second place was United Kingdom (10%), followed by Australia (4%).
New pipeline Drug Delivery medical devices: Expected to be approved by 2025
According to GlobalData, approximately 65% of pipeline Drug Delivery Devices in 2021 were expected to receive regulatory approval by the end of 2025. The leading categories for devices expected to receive regulatory approval by the end of 2025 was Dry Powder Inhaler Devices, at 4% of devices. Differences in regulatory approval timelines reflect the stage of development for a device, the device complexity or risk categorization (or device class) or if there are changes in regulatory oversight.
Nemera La Verpilliere tops Drug Delivery Devices development in 2021
According to GlobalData, top ten medical device companies accounted for 22.37% of pipeline Drug Delivery Devices activity during 2021. The leading company for developing Drug Delivery Devices was Nemera La Verpilliere with 3.95%, followed by SynAgile Corp at 3.29%.
Companies launching new medical devices are more likely to disrupt existing market share or are better able to defend existing share.
Company-developed pipeline products lead Drug Delivery Devices in development
Looking at the share of activity in terms of Drug Delivery pipeline products developers, company-developed pipeline products accounted for an 86% share of the Drug Delivery medical devices market, while institute-developed pipeline products held the remaining share.
The monthly average for 2021 saw company-developed Drug Delivery pipeline products account for 86% of pipeline products and institute-developed pipeline products account for 14%.
The medical devices pipeline data used in this article were extracted from Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database covers all medical devices which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. Pipeline products are covered from various authenticated sources like company websites, SEC filings, conference presentations, analyst presentations, news releases, grants etc. The information is collected by following systematic research techniques and proprietary methodology.